Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 0 gemcitabine microdosing pharmacokinetic study
NL-OMON45398Phase 0Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 0, open-label, single-arm trial of gemcitabine in non-small cell lung cancer (NSCLC), bladder cancer and mesothelioma, sponsored by Netherlands Cancer Institute. Primary endpoints: Pharmacokinetics after microdose gemcitabine and Pharmacokinetics after therapeutic-dose gemcitabine. Started May 2017; status: active, not recruiting.
02
Drugs
gemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)bladder cancermesothelioma
Beyond the preview
Go deeper on NL-OMON45398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45398.